Ombitasvir
Chemical compound
Pharmaceutical compound
Ombitasvir Trade names
Viekira Pak, Viekira XR (with ombitasvir, paritaprevir, ritonavir and dasabuvir),
Technivie (with ombitasvir, paritaprevir, and ritonavir) Other names ABT-267 License data
Routes of By mouth (tablets )Legal status Bioavailability Not determined Protein binding ~99.9% Metabolism Amide hydrolysis followed by oxidation Onset of action ~4 to 5 hours Elimination half-life 21 to 25 hours Excretion Mostly with feces (90.2%)
Dimethyl N ,N ′-{[(2S ,5S )-1-(4-tert -butylphenyl)pyrrolidene-2,5-diyl]-bis-{[(4,1-phenyleneazanediyl)carbonyl] [(2S )-pyrrolidine-2,1-diyl]}[(2S )-3-methyl-1-oxobutane-1,2-diyl])}biscarbamate
CAS Number PubChem CID ChemSpider UNII KEGG ChEBI CompTox Dashboard (EPA ) Formula C 50 H 67 N 7 O 8 Molar mass −1 3D model (JSmol )
CC(C)[C@@H](C(=O)N1CCC[C@H]1C(=O)Nc2ccc(cc2)[C@@H]3CC[C@H](N3c4ccc(cc4)C(C)(C)C)c5ccc(cc5)NC(=O)[C@@H]6CCCN6C(=O)[C@H](C(C)C)NC(=O)OC)NC(=O)OC
InChI=1S/C50H67N7O8/c1-30(2)42(53-48(62)64-8)46(60)55-28-10-12-40(55)44(58)51-35-20-14-32(15-21-35)38-26-27-39(57(38)37-24-18-34(19-25-37)50(5,6)7)33-16-22-36(23-17-33)52-45(59)41-13-11-29-56(41)47(61)43(31(3)4)54-49(63)65-9/h14-25,30-31,38-43H,10-13,26-29H2,1-9H3,(H,51,58)(H,52,59)(H,53,62)(H,54,63)/t38-,39-,40-,41-,42-,43-/m0/s1
Key:PIDFDZJZLOTZTM-KHVQSSSXSA-N
Ombitasvir is an antiviral drug for the treatment of hepatitis C virus (HCV) infection by AbbVie . In the United States, it is approved by the Food and Drug Administration for use in combination with paritaprevir , ritonavir and dasabuvir in the product Viekira Pak for the treatment of HCV genotype 1,[ 1] [ 2] paritaprevir and ritonavir in the product Technivie for the treatment of HCV genotype 4.[ 3] [ 4]
Ombitasvir is an NS5A inhibitor that acts by inhibiting the HCV protein NS5A .[ 5]
See also
References
^ "VIEKIRA PAK™ (ombitasvir, paritaprevir and ritonavir tablets; dasabuvir tablets), for Oral Use. Full Prescribing Information" (PDF) . AbbVie Inc., North Chicago, IL 60064. Archived from the original (PDF) on 2 May 2019. Retrieved 30 July 2015 .^ "FDA approves Viekira Pak to treat hepatitis C" . Food and Drug Administration . December 19, 2014.^ "TECHNIVIE™ (ombitasvir, paritaprevir and ritonavir) Tablets, for Oral Use. Full Prescribing Information" (PDF) . AbbVie Inc., North Chicago, IL 60064. Archived from the original (PDF) on 19 January 2019. Retrieved 28 July 2015 .^ "FDA approves Technivie for treatment of chronic hepatitis C genotype 4" . Food and Drug Administration . July 24, 2015.^ Feld JJ, Kowdley KV, Coakley E, Sigal S, Nelson DR, Crawford D, et al. (April 2014). "Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin" (PDF) . The New England Journal of Medicine . 370 (17): 1594–603. doi :10.1056/NEJMoa1315722 . PMID 24720703 .
Further reading
Grebely J, Puoti M, Wedemeyer H, Cooper C, Sulkowski MS, Foster GR, et al. (November 2018). "Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin in Patients With Chronic Hepatitis C Virus Genotype 1 Infection Receiving Opioid Substitution Therapy: A Post Hoc Analysis of 12 Clinical Trials" . Open Forum Infectious Diseases . 5 (11): ofy248. doi :10.1007/s15010-018-1157-x . OCLC 1105037362 . PMC 6222025 PMID 30430131 . Petta S, Marzioni M, Russo P, Aghemo A, Alberti A, Ascione A, et al. (June 2017). "Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study". The Lancet. Gastroenterology & Hepatology . 2 (6): 427–434. doi :10.1016/S2468-1253(17)30048-1 . hdl :11390/1119739 PMID 28497758 .
